Hints and tips:
Related Special Reports
...In 2013, KKR acquired Panasonic’s healthcare division, a business it listed in 2021. It also owns assets ranging from supermarket chain Seiyu to semiconductor manufacturer Kokusai Electric....
...In September, Carlyle shut its US consumer, media and retail private equity investment group and dismissed some investment staff....
...The sector has trillions of dollars invested in industries from real estate and healthcare to energy and manufacturing....
...Nelson Peltz’s activist hedge fund Trian Partners has built a stake in Unilever, ratcheting up the pressure on the FTSE 100 company after its abortive pursuit of GlaxoSmithKline’s consumer health business...
...“But from a consumer perspective, you also want the payments to be enough that you can still get access to care.”...
...Peltz had built a stake in the early months of 2022, after Unilever’s share price slumped following its botched attempt to buy GlaxoSmithKline’s consumer healthcare arm, later spun out as Haleon....
...L Catterton, a consumer-focused investment firm, has hired Peter Chang as managing partner and co-head of private credit. He joins from Oaktree Capital Management....
...Haleon, GlaxoSmithKline’s consumer healthcare venture with Pfizer, is down about 5 per cent from its July listing price....
...However, Smith pointed out that despite attracting attention for his technology investments, the sector is only the third-largest in his fund, behind healthcare and consumer staples....
...GlaxoSmithKline’s chief executive said a shareholder vote in favour of spinning off its consumer healthcare business vindicated the UK drugmaker’s decision to turn down a £50bn takeover offer from Unilever...
...’s consumer health division....
...GlaxoSmithKline: shingle minded Worried about shingles? GlaxoSmithKline is....
...The consumer health spin-off will give GSK more money to spend on deals and invest in research and development....
...Its failed attempts to buy UK drugmaker GlaxoSmithKline’s consumer healthcare business, a politically fraught fight with Ben & Jerry’s and the arrival of the billionaire activist Nelson Peltz on Unilever...
...GlaxoSmithKline chief executive Emma Walmsley said the imminent spin-off of the consumer health division Haleon would untangle the UK drugmaker’s complex “Gordian knot” structure and enable her to tackle...
...Pfizer will sell down its stake in Haleon, its consumer health joint venture with GlaxoSmithKline, after a London listing planned for July 18....
...Emma Walmsley, the drugmaker’s chief executive, said it had delivered “strong first-quarter results in this landmark year for GSK”, as it prepared to spin off its consumer healthcare division into a company...
...Unilever has said it will not increase its offer for GSK Consumer Healthcare above £50bn, drawing a line under its pursuit of the division owned by GlaxoSmithKline and Pfizer after a backlash from investors...
...Unilever has defended its plan to acquire the consumer health division of GlaxoSmithKline following scepticism from analysts about its £50bn bid....
...GlaxoSmithKline expects to spin off its consumer healthcare joint venture Haleon in July, as the UK drugmaker presses on with plans for the largest demerger in Europe in the past 20 years....
...Then came this weekend’s revelation that Unilever had made three approaches to buy the consumer healthcare unit being spun off by GlaxoSmithKline....
...GlaxoSmithKline and Pfizer are holding out for an improved bid of at least £60bn for their consumer healthcare joint venture, bolstered by shareholder opposition to Unilever’s £50bn offer....
...following its abortive pursuit of GlaxoSmithKline’s consumer health business....
International Edition